Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enlicitide decanoate - Merck Sharp & Dohme

Next Previous
Drug Profile

Enlicitide decanoate - Merck Sharp & Dohme

Alternative Names: Enlicitide Chloride; MK-0616

Latest Information Update: 08 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme Corp.
  • Class Antihyperlipidaemics; Cyclic peptides; Urologics
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypercholesterolaemia; Hyperlipoproteinaemia type IIa

Most Recent Events

  • 02 Sep 2025 Topline efficacy and adverse events data from the phase III CORALreef Lipids trial in Hypercholesterolaemia released by Merck Sharp & Dohme Corp.
  • 02 Sep 2025 Merck Sharp & Dohme completes enrolment in the phase III CORALreef Outcomes trial in Hypercholesterolaemia (Treatment-experienced) in USA, Argentina, Australia, Taiwan, Brazil, Canada, China, Chile, Colombia, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Norway, Peru, Poland, Puerto Rico, South Africa, South Korea, Spain, Turkey, and United Kingdom (PO), prior to September 2025 (NCT06008756)
  • 21 Aug 2025 Phase-II/III clinical trials in Hyperlipoproteinaemia type IIa (In children, In adolescents, Treatment-experienced) in USA (PO) (NCT07058077)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top